Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-10-04
2011-11-01
Ward, Paul V. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C540S145000
Reexamination Certificate
active
08048906
ABSTRACT:
Organic chelating ligands, organic chelating ligand precursors, and metal chelates are disclosed. Methods for synthesizing the same are also described, including methods for preparing optically-enriched or optically-pure compositions of the same.
REFERENCES:
patent: 4880008 (1989-11-01), Lauffer
patent: 4899755 (1990-02-01), Lauffer et al.
patent: 6406297 (2002-06-01), Raymond et al.
patent: 6515113 (2003-02-01), Raymond et al.
patent: 6549798 (2003-04-01), Stefancik et al.
patent: 6652835 (2003-11-01), Lauffer et al.
patent: WO 96/23526 (1996-08-01), None
patent: WO 01/08712 (2001-02-01), None
patent: WO 01/09188 (2001-02-01), None
patent: WO 02/24235 (2002-03-01), None
Woods et al., “Correlation of Water Exchange Rate with Isomeric Composition in Diastereoisomeric Gadolinium Complexes of Tetra(carboxyethyl)dota and Related Macrocyclic Ligands,”J. Am. Chem. Soc., 2000, 122:9781-9792.
André et al., “High Relaxivity for Monomeric Gd(DOTA)-Based MRI Contrast Agents, Thanks to Micellar Self-Organization,”Chem. Eur. J., 1999, 5(10):2977-2983.
Caravan et al., “Gadolinium(III) Chelates as MRI Contrast Agents: Structure, Dynamics, and Applications,”Chem. Rev., 1999, 99:2293-2352.
“2001 Guidelines for Authors,”J. Org. Chem., 2001, 66(1):18A-24A.
Jones (ed.), “A Short Guide to Abbreviations and Their Use in Peptide Science,”J. Peptide Sci., 1999, 5:465-471.
Mummert et al., “Development of a Peptide Inhibitor of Hyaluronan-mediated Leukocyte Trafficking,”J. Exp. Med., 2000, 192(6):769-779.
Nielsen et al., “Identification of a Major Heparin and Cell Binding Site in the LG4 Module of the Laminin α5 Chain,”J. Biol. Chem., 2000, 275(19):14517-14523.
Cai et al., “Synthesis of CMI-977, a Potent 5-Lipoxygenase Inhibitor,”Organic Process Research&Development, 1999, 3:73-76.
Crossland et al., “Sulfonate Leaving Groups, Structure and Reactivity. 2,2,2-Trifluoroethanesulfonate,”J. Am. Chem. Soc., 1971, 93(17):4217-4219.
Doolittle and Heath, “(S)-Tetrahydro-5-oxo-2-furancarboxylic Acid: A Chiral Derivatizing Reagent for Asymmetric Alcohols,”J. Org. Chem., 1984, 49:5041-5050.
Eisenwiener et al., “A Convenient Synthesis of Novel Bifunctional Prochelators for Coupling to Bioactive Peptides for Radiometal Labelling,”Bioorg. Med. Chem. Lett., 2000, 10:2133-2135.
Gringore and Rouessac, “(S)-(+)-γ-Butyrolactone-γ-Carboxylic Acid (2-Furancarboxylic acid, tetrahydro-5-oxo-, (S)-),”Organic Syntheses, 1985, 63:121-126.
Hoffmann and Wasielewski, “Synthesis of Depsipeptides, Part XI*, Synthesis of Didepsipeptides of D-α-Hydroxyglutaric Acid,”Roczniki Chem., 1975, 49:151-158.
Jacques and Desreux, “Synthesis of MRI Contrast Agents II. Macrocyclic Ligands,”The Chemistry of Contrast Agents in Medical Magnetic Resonance Imaging, 2001, Meerbach and Tóth (eds.), John Wiley and Sons, New York, NY, pp. 157-191.
Kang et al., “Synthesis, Characterization, and Crystal Structure of the Gadolinium(III) Chelate of (1R,4R,7R)-α,α′,αΔ-Trimethyl-1,4,7,10-tetraazacyclododecane-1,4,7-triacetic Acid (DO3MA),”Inorg. Chem., 1993, 32:2912-2918.
Okabe et al., “Synthesis of the Dideoxynucleosides ddC and CNT from Glutamic Acid, Ribonolactone, and Pyrimidine Bases,”J. Org. Chem., 1988, 53:4780-4786.
Schmidt et al., “Enantioselective Syntheses of (R)- and (S)-Hexahydropyridazine-3-carboxylic Acid Derivatives,”Synthesis, 1996, pp. 223-229.
Shin et al., “Synthesis of Optically Active Phthaloylimg id="CUSTOM-CHARACTER-00001" he="2.46mm" wi="2.12mm" file="US08048906-20111101-P00001.TIF" alt="custom character" img-content="character" img-format="tif" ?-Aminooxy Acids fromimg id="CUSTOM-CHARACTER-00002" he="2.46mm" wi="2.12mm" file="US08048906-20111101-P00002.TIF" alt="custom character" img-content="character" img-format="tif" ?-Amino Acids orimg id="CUSTOM-CHARACTER-00003" he="2.46mm" wi="2.12mm" file="US08048906-20111101-P00003.TIF" alt="custom character" img-content="character" img-format="tif" ?-Hydroxy Acids as Building Blocks for the Preparation of Aminooxy Peptides,”J. Org. Chem., 2000,65:7667-7675.
Streitwieser Jr. et al., “Kinetics and Isotope Effects in Solvolyses of Ethyl Trifluoromethanesulfonate,”J. Am. Chem. Soc., 1968, 90(6):1598-1601.
Vigneron et al., “L'Eldanolide, Phéromone Des Glandes Alaires De La Pyrale De La Canne à Sucre,Eldana Saccharina(Wlk.): Structure et Synthèse De Ses Deux Ènantioméres,”Tetrahedron, 1984, 40(18):3521-3529 (includes English language Abstract).
Zamzow and Höcker, “Synthesis of polymers with pendant spiro orthoester groups,”Macromol. Chem. Phys., 1994, 195:2381-2400.
Amedio John C.
Caravan Peter D.
Greenfield Matthew
Jacques Vincent
Kalogeropoulos Shirley
Catalyst Medical
Fish & Richardson P.C.
Ward Paul V.
LandOfFree
Optically pure and enriched isomers of chelating ligands and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Optically pure and enriched isomers of chelating ligands and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Optically pure and enriched isomers of chelating ligands and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4291765